A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507728-22-00

Acronym

BP43015

Enrollment

Registered

2024-06-25

Start date

2021-06-25

Completion date

Unknown

Last updated

2025-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Denmark, Italy, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026